載入...
Bioavailability, safety, and pharmacodynamics of delayed-release dexlansoprazole administered as two 30 mg orally disintegrating tablets or one 60 mg capsule
BACKGROUND: Dual delayed-release dexlansoprazole is approved for use in adults as a 30 mg orally disintegrating tablet (ODT) or as 30 mg and 60 mg capsules. The pharmacokinetics, pharmacodynamics, and safety profile of two dexlansoprazole 30 mg ODTs were compared with one dexlansoprazole 60 mg capsu...
Na minha lista:
| 發表在: | Therap Adv Gastroenterol |
|---|---|
| Main Authors: | , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
SAGE Publications
2016
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5076775/ https://ncbi.nlm.nih.gov/pubmed/27803732 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1756283X16666800 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|